Meeting
2024 ASCO Genitourinary Cancers Symposium
Identification of a panel of microRNA biomarkers for the management of patients with refractory germ cell tumor of the testis.
Authors
Jim Zhongning Chen
Division of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR
Jim Zhongning Chen , Ahmet Aydin , Neriman Gokden , Timothy Langford , Shi-Ming Tu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 521)
DOI
10.1200/JCO.2024.42.4_suppl.521
Abstract #
521
Poster Bd #
M1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Viable germ cell tumor and teratoma can be distinguished from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens by a combination of microRNA-371a-3p and 375-5p.
First Author: Tim Nestler
Poster
2020 Genitourinary Cancers Symposium
Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.
First Author: Nirmish Singla
Poster
2014 Genitourinary Cancers Symposium
Multicenter sequential phase II study of flavopiridol plus oxaliplatin (alvocidib) with or without 5-FU and leucovorin (LV) for patients (pts) with refractory germ cell tumors (GCT) including late relapse (LR).
First Author: Darren Richard Feldman
Poster
2012 Genitourinary Cancers Symposium
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) as third- to fourth-line therapy for male germ cell tumors (GCT).
First Author: Andrea Necchi